Novacyt S.A. (OTC:NVYTF) announces that
it has sold, received orders or has contracted to deliver over £90
million (€103 million) of its COVID-19 polymerase chain reaction (PCR)
test, including a supply agreement with the UK’s Department of Health
and Social Care and initial orders from its collaboration with
AstraZeneca (NYSE:AZN), GlaxoSmithKline (NYSE:GSK) and the University of Cambridge.
It is now supplying the test to over 100
countries, including the U.S., adding that it should be able to produce
~8M tests/month by June via its own manufacturing sites (two) and six
sub-contract manufacturers.
Aimed at addressing the global shortage of certain
extraction reagents, it is developing new extraction technology that
eliminates the use of magnetic beads that it expects to launch in May.
On the financial results front, it expects to release 2019 results during the week of May 11.
https://seekingalpha.com/news/3565870-novacyt-seeing-strong-demand-for-covidminus-19-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.